Compare ATCX & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATCX | NCEL |
|---|---|---|
| Founded | 2016 | 2008 |
| Country | Brazil | Switzerland |
| Employees | 13 | 4 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.5M | 20.6M |
| IPO Year | N/A | N/A |
| Metric | ATCX | NCEL |
|---|---|---|
| Price | $3.78 | $3.01 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $13.75 | N/A |
| AVG Volume (30 Days) | 22.9K | ★ 26.1K |
| Earning Date | 03-16-2023 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $827,667.00 | N/A |
| Revenue Next Year | $166.45 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.77 | $1.83 |
| 52 Week High | $14.01 | $5.12 |
| Indicator | ATCX | NCEL |
|---|---|---|
| Relative Strength Index (RSI) | 26.04 | 43.41 |
| Support Level | N/A | $2.50 |
| Resistance Level | $5.62 | $3.16 |
| Average True Range (ATR) | 0.35 | 0.27 |
| MACD | -0.07 | -0.04 |
| Stochastic Oscillator | 3.45 | 14.99 |
Atlas Critical Minerals Corp is a mineral exploration and development company focused on critical minerals projects and properties in Brazil. The company's portfolio principally includes mineral properties for rare earths, graphite, titanium, copper, uranium, and nickel. It also owns mineral rights for iron ore, quartzite, gold, and diamond properties. The company's project portfolio includes the Alto Paranaiba, Malacacheta, Arcos, Goias, Tocantins, Rio Piracicaba, and other projects.
NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.